Teva Pharmaceutical Industries Limited (TEVA) Financial Statements
Historical financial data — 34 statements covering FY2017–FY2025
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total nu...
Teva Pharmaceutical Industries Limited's revenue increased 4.3% year over year, from $16.54B to $17.26B.
Net income increased 186.0% over the same period, from $-1.64B to $1.41B.
Over the 8-year period from FY2017 to FY2025, revenue declined by 23% in total.
Total debt remained relatively stable at $1.82B.
The debt-to-equity ratio stands at 0.23, indicating a conservative leverage profile.
Operating cash flow grew 32.2% to $1.65B.
Teva Pharmaceutical Industries Limited maintains a moderate net profit margin of 8.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $4.16B+9.0% | $-846.0M | $2.02B | $-5.0M | $103.0M | $41.34B | $2.09B | $6.36B |
| Q3 FY2024 | $4.33B+4.0% | $-437.0M | $2.15B | $-51.0M | $693.0M | $41.76B | $2.58B | $6.07B |
| Q4 FY2024 | $4.23B-2.4% | $-217.0M | $2.12B | $-29.0M | $575.0M | $39.33B | $1.78B | $5.37B |
| Q1 FY2025 | $3.89B-8.0% | $214.0M | $1.88B | $519.0M | $-105.0M | $38.41B | $421.0M | $6.26B |
| Q2 FY2025 | $4.18B+7.3% | $283.0M | $2.10B | $456.0M | $227.0M | $40.13B | $464.0M | $6.83B |
| Q3 FY2025 | $4.48B+7.3% | $433.0M | $2.30B | $882.0M | $369.0M | $39.86B | $24.0M | $7.25B |
| Q4 FY2025 | $4.71B+5.2% | $480.0M | $2.66B | $300.0M | $1.16B | $40.75B | $1.82B | $7.91B |
| Q1 FY2026 | $3.98B-15.5% | $369.0M | $1.97B | $652.0M | $-40.0M | $40.04B | $2.61B | $8.23B |
Balance Sheet Summary (Latest Period)
Teva Pharmaceutical Industries Limited (TEVA) Financial Statements & Revenue History
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $39.19 with a market capitalization of $46. This page provides 34 historical financial statements for Teva Pharmaceutical Industries Limited, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Teva Pharmaceutical Industries Limited reported revenue of $17.3 billion, representing 4.3% year-over-year growth. The net profit margin of 8.2% indicates moderate profitability. The debt-to-equity ratio of 0.23 shows conservative leverage.
TEVA Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Teva Pharmaceutical Industries Limited's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether TEVA is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track TEVA's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Teva Pharmaceutical Industries Limited converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of TEVA's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use TEVA Financial Data
Investors use Teva Pharmaceutical Industries Limited's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare TEVA's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how TEVA's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View TEVA's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Teva Pharmaceutical Industries Limited's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.TEVA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.